Physician profile
Robert Wayne Calcote
NPI 1730243502
$1,967.94
in general payments reported to CMS, 2019-2025
18 companies · $177 in 2025
The $177 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $220 · 2021: $517 · 2022: $276 · 2023: $431 · 2024: $190 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $341.33 | 2022-2024 | Sotyktu |
| Abbvie INC. | $301.35 | 2021-2025 | |
| Leo Pharma INC. | $244.74 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $204.65 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $172.30 | 2020-2024 | |
| Sun Pharmaceutical Industries INC. | $159.72 | 2019-2022 | |
| Ucb, INC. | $122.30 | 2021 | |
| Janssen Biotech, INC. | $85.64 | 2019-2022 | |
| Pfizer INC. | $82.41 | 2019-2023 | |
| Galderma Laboratories, L.P. | $60.09 | 2021-2025 | Nemluvio |
| Amgen INC. | $53.49 | 2022-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $33.23 | 2024 | Dupixent |
| Dusa Pharmaceuticals, INC. | $20.48 | 2019 | |
| Mission Pharmacal Company | $18.26 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.68 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $17.29 | 2025 | Sofdra |
| Lilly USA, LLC | $16.99 | 2021 | |
| Strata Skin Sciences, INC. | $15.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Calcote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.